Sugi Predict

Sugi Predict / Compounds / SCHEMBL437460

SCHEMBL437460

SCHEMBL437460

COC(=O)Cc1coc2cc(O)ccc12

nearest known ligand 0.67

Predicted protein targets (top 16)

geneUniProtsupporting neighboursconfidence
▸ GAA P10253 2/20 0.67
▸ KDM4E B2RXH2 2/20 0.67
▸ ALDH1A1 P00352 2/20 0.67
▸ GLA P06280 1/20 0.67
▸ MEN1 O00255 1/20 0.67
▸ POLB P06746 1/20 0.67
▸ KMT2A Q03164 1/20 0.67
▸ L3MBTL1 Q9Y468 2/20 0.53
▸ PIM1 P11309 1/20 0.52
▸ MAPT P10636 3/20 0.51
▸ SMN1; SMN2 Q16637 2/20 0.51
▸ ALOX15 P16050 1/20 0.51
▸ TDP1 Q9NUW8 1/20 0.51
▸ HPGD P15428 1/20 0.48
▸ TSHR P16473 2/20 0.47
▸ HSD17B3 P37058 1/20 0.47

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL24950352 0.88 GAA (0.56) GAAKDM4EALDH1A1GLAMEN1
SCHEMBL9979457 0.86 GAA (0.75) GAAKDM4EALDH1A1GLAMEN1
SCHEMBL14564359 0.85 MAPT (0.71) GAAALDH1A1MEN1POLBKMT2A
SCHEMBL2431256 0.84 ALDH1A1 (0.67) GAAKDM4EALDH1A1MEN1KMT2A
SCHEMBL4231514 0.83 MAPT (0.52) GAAKDM4EALDH1A1GLAMEN1
SCHEMBL205825 0.81 ALOX15 (0.69) GAAMEN1POLBKMT2AL3MBTL1
SCHEMBL3133971 0.80 POLB (0.56) GAAKDM4EALDH1A1MEN1POLB
SCHEMBL734054 0.80 KDM4E (0.55) KDM4EALDH1A1MAPT
SCHEMBL533173 0.80 ALDH1A1 (1.00) GAAKDM4EALDH1A1GLAKMT2A
SCHEMBL16448790 0.79 HSD17B3 (0.60) GAAKDM4EALDH1A1MEN1POLB

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 178 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-12590062-B2 PD-1/PD-L1 inhibitors GILEAD SCIENCES, INC. (US) 2026-03-31 — — US disclosed
CN-115504972-B Isoxazole derivatives, preparation method thereof and application thereof as medicines 广东药科大学 2024-11-12 — — CN disclosed
CN-112480047-B Compound with blood glucose reducing and lipid regulating effects, preparation and application thereof 云南省第二人民医院 2023-06-02 — — CN disclosed
CN-115504972-A Isoxazole derivatives, preparation method thereof and application thereof as medicines 广东药科大学 2022-12-23 — — CN disclosed
EP-4026835-A2 PD-1/PD-L1 INHIBITORS Gilead Sciences, Inc. (US) 2022-07-13 — — EP disclosed
EP-4026835-A2 PD-1/PD-L1 INHIBITORS Gilead Sciences, Inc. (US) 2022-07-13 — — EP disclosed
US-11377450-B2 Functionalized heterocycles as antiviral agents ENANTA PHARMACEUTICALS, INC. (US) 2022-07-05 — — US disclosed
US-20210323922-A1 PD-1/PD-L1 INHIBITORS GILEAD SCIENCES, INC. (US) 2021-10-21 — — US disclosed
EP-3852751-A1 FUNCTIONALIZED HETEROCYCLES AS ANTIVIRAL AGENTS Enanta Pharmaceuticals, Inc. (US) 2021-07-28 — — EP disclosed
CN-112955142-A Functionalized heterocyclic compounds as antiviral agents 英安塔制药有限公司 2021-06-11 — — CN disclosed
US-20060014785-A1 BICYCLIC, SUBSTITUTED TRIAZOLES AS MODULATORS OF PPAR AND METHODS OF THEIR PREPARATION METABOLEX, INC. (US) 2006-01-19 — — US disclosed
WO-2005115384-A2 BICYCLIC, SUBSTITUTED TRIAZOLES AS MODULATORS OF PPAR AND METHODS OF THEIR PREPARATION METABOLEX, INC. (US) 2005-12-08 — — WO disclosed
EP-1585726-A1 FUSED HETEROCYCLIC DERIVATIVES AS PPAR MODULATORS ELI LILLY AND COMPANY (US) 2005-10-19 — — EP disclosed
EP-1581521-A1 FUSED HETEROCYCLIC DERIVATIVES AS PPAR MODULATORS ELI LILLY AND COMPANY (US) 2005-10-05 — — EP disclosed
WO-2005066136-A1 BICYCLIC DERIVATIVES AS PPAR MODULATORS ELI LILLY AND COMPANY (US) 2005-07-21 — — WO disclosed
US-6875780-B2 Compounds that modulate PPAR activity and methods for their preparation WARNER-LAMBERT COMPANY (US) 2005-04-05 — — US disclosed
WO-2004091604-A1 COMPOUNDS THAT MODULATE PPAR ACTIVITY AND METHODS OF PREPARATION WARNER-LAMBERT COMPANY LLC (US) 2004-10-28 — — WO disclosed
US-20040209936-A1 Compounds that modulate PPAR activity and methods of preparation BRATTON LARRY D (US) 2004-10-21 — — US disclosed
WO-2004063190-A1 FUSED HETEROCYCLIC DERIVATES AS PPAR MODULATORS ELI LILLY AND COMPANY (US) 2004-07-29 — — WO disclosed
WO-2004063155-A1 FUSED HETEROCYCLIC DERIVATIVES AS PPAR MODULATORS ELI LILLY AND COMPANY (US) 2004-07-29 — — WO disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (5 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-11377450-B2 Functionalized heterocycles as antiviral agents HCCS, HAVCR2, HDGF GAA 937/4885KDM4E 1899/4885ALDH1A1 2352/4885
US-20210323922-A1 PD-1/PD-L1 INHIBITORS CD274, PDCD1, PDCD1LG2 GAA 1061/4885KDM4E 1276/4885ALDH1A1 104/4885
US-20040209936-A1 Compounds that modulate PPAR activity and methods of preparation PPARA, PPARG, PPARD GAA 486/4885KDM4E 2473/4885ALDH1A1 1771/4885
US-20060014785-A1 BICYCLIC, SUBSTITUTED TRIAZOLES AS MODULATORS OF PPAR AND METHODS OF THEIR PREPARATION PPARG, PPARD, GPR119 GAA 1072/4885KDM4E 3515/4885ALDH1A1 2102/4885
US-12590062-B2 PD-1/PD-L1 inhibitors CD274, PDCD1LG2, PDCD1 GAA 3510/4885KDM4E 1970/4885ALDH1A1 409/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.